Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial (3ACT)
Can Triple Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria, Delay Drug Resistance Development of Plasmodium Falciparum in Tanzania: a Randomized Three Arm Clinical Trial
Sponsor: Muhimbili University of Health and Allied Sciences
This PHASE2/PHASE3 trial investigates Uncomplicated Plasmodium Falciparum Malaria and is currently actively recruiting participants. Muhimbili University of Health and Allied Sciences leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
4 versions recorded-
Jan 2025 — Present [monthly]
Recruiting PHASE2/PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Muhimbili University of Health and Allied Sciences
- The Swedish Research Council
- Uppsala University
For direct contact, visit the study record on ClinicalTrials.gov .